Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Leukemia Research|June 3, 2021
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional databaseDouglas Tremblay, Lukas Ronner, Nikolai Podoltsev, et al.
Haematologica|February 1, 2024
Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemiaAkriti G Jain, Somedeb Ball, Luis Aguirre, et al.
Leukemia|May 5, 2023
Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromesLuis E Aguirre, Najla Al Ali, David A Sallman, et al.
Blood Neoplasia|June 2, 2025
Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasmZhuoer Xie, Najla Al Ali, Ling Zhang, et al.
Leukemia Research|May 15, 2020
Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancyChetasi Talati, Aaron D Goldberg, Amanda Przespolewski, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 22, 2023
Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and OutcomesSara M Tinsley-Vance, Najla Al Ali, Somedeb Ball, et al.
American Journal of Hematology|September 14, 2023
Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemiaParth C Patel, Somedeb Ball, Akriti G Jain, et al.
Annals of Hematology|July 2, 2026
Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014-2024)Utsav Joshi, Fatima Tuz Zahra, Pujan Patel, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 1, 2024
Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell TransplantFilip Ionescu, Jerel C David, Apoorva Ravichandran, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 9, 2023
Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene FusionYumeng Zhang, Lynn Nguyen, Chuanyi M Lu, et al.
Pageof 4